Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016027259 - CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE

Publication Number WO/2016/027259
Publication Date 25.02.2016
International Application No. PCT/IB2015/056356
International Filing Date 21.08.2015
IPC
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/22 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
22Anxiolytics
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 31/09
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
085having an ether linkage to aromatic ring nuclear carbon
09having two or more such linkages
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61K 31/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K 31/4515
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4515having a butyrophenone group in position 1, e.g. haloperidol
Applicants
  • TARGIA PHARMACEUTICALS [IL]/[IL]
Inventors
  • GLOZMAN, Sabina
Priority Data
62/040,33221.08.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
(FR) COMPOSITIONS PHARMACEUTIQUES POUR LE SYSTÈME NERVEUX CENTRAL ET PROCÉDÉS D'UTILISATION
Abstract
(EN)
The present invention is directed to pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a central nervous system (CNS) active agent and pseudoephedrine (PSE), phenylephrine (PHE), or both. In some embodiments, the pharmaceutical compositions further comprise a mechanoreceptor stimulator. The PSE, PHE and the mechanoreceptor stimulator are in an amount sufficient to reduce a side-effect of the CNS active agent. The methods of reducing side-effects of a CNS active agent comprises administering the CNS active agent and administering PSE, PHE, or both to the subject, wherein the administration of the CNS active agent and the PSE and/or PHE is synchronized and there is chronological overlap in physiological activity of the CNS active agent and of PSE and/or PHE.
(FR)
La présente invention concerne des compositions pharmaceutiques et des procédés d'utilisation. Lesdites compositions pharmaceutiques comprennent un agent actif sur le SNC et de la pseudoéphédrine (PSE), de la phényléphrine (PHE), ou les deux. Dans certains modes de réalisation, les compositions pharmaceutiques comprennent en outre un stimulateur mécanorécepteur. La PSE, la PHE et le stimulateur mécanorécepteur sont présents dans une quantité suffisante pour réduire un effet secondaire de l'agent actif sur le SNC. Les procédés destinés à réduire les effets secondaires d'un agent actif sur le SNC comprennent l'administration de l'agent actif sur le SNC et l'administration de PSE, de PHE, ou des deux au sujet, ladite administration de l'agent actif sur le SNC et de la PSE et/ou de la PHE étant synchronisée, de sorte qu'il y a chevauchement chronologique dans l'activité physiologique de l'agent actif sur le SNC et de la PSE et/ou la PHE.
Also published as
Latest bibliographic data on file with the International Bureau